Infermedica: Funding, Investors & Team (Sep 2026)

Infermedica, a leading digital health company, tackles the problem of inappropriate use of medical services and misdiagnosis, providing insurance companies, hospitals, and health systems with a set of AI-powered preliminary diagnosis and triage solutions. “The broader goal is to improve customers’ performance, increase healthcare accessibility, and reduce costs. To date, our tools have been used by over 6 million users worldwide, and we are working with more than 50 companies, including Allianz Worldwide Partners, Microsoft, Global Excel, Médis, PZU Zdrowie, Sana Kliniken or Everyday Health,” says Piotr Orzechowski, Infermedica’s CEO. The company uses artificial intelligence and machine learning to assess symptoms and find patterns in data. Thanks to algorithms, Infermedica gets smarter over time. Additionally, the team of physicians verifies every piece of information that is added to the medical database to ensure that patients get safe and reliable recommendations. To date, physicians involved in the project have spent over 30,000 hours on reviews. Over the last year, Infermedica grew into a team of over 100 people, and its products were translated into 17 languages, making them available in countries such as China and the United Arab Emirates. The latest investment round of $10.25M will help to expand market presence in the United States and Europe, and accelerate the development of the technology.

Infermedica has raised $40.3M across 2 rounds on record. The most recent is a Series B of $30.0M announced in Jan 2022.

Infermedica's most recent funding round on record is a Series B of $30.0M, announced in Jan 2022.

Piotr Orzechowski is listed as CEO at Infermedica.

Infermedica is based in Wroclaw, Dolnoslaskie, Poland.

Infermedica is in the 101-250 employee band.

Infermedica's latest round of $30.0M is above the $5.5M median round size for Artificial Intelligence companies on FundedIQ across 7,233 tracked companies over the last two years.